This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 03 17 pharma-law-policy-research
Remove 2023 Related Topics
Health Care Access Ransomware Payment Systems Medicaid Fraud Health Insurance Medicare Health Services Administration Nursing Homes Governance More Related Topics >
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – March And April

SQA

MAY 24, 2023

ANVISA Resumes Inspections in the Area of Technovigilance, 29 March 2023 In partnership with local Health Surveillance, ANVISA technical teams carried out in March 2023 two (2) medical device manufacturer inspections with an aim to strengthen the monitoring of these products in Brazil, ensuring their safety, performance, and quality.

FDA 40
FDA Licensing Governance Compliance 40
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

DECEMBER 16, 2022

ANVISA published answers to questions received during an online seminar on clinical research of medicinal cannabis held in May 2022. The changes will serve to strengthen the country’s medical device registration regulations upon their effective date of 01 March 2023. implementation date: 01 January 2023).

FDA 40
FDA Compliance COVID-19 Licensing 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 50,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024